Biomaterial Database

Use of etidronate (EHDP) in Paget's disease of bone. 1980

C C Johnston, and M R Khairi, and P J Meunier

Etidronate used in recommended doses (usually 5 mg/kg/day for 6 months) produces symptomatic improvement in approximately 60% of patients. The serum alkaline phosphatase and urinary hydroxyproline are reduced to about 50% of initial values. A sustained remission occurs in many patients and retreatment is usually effective upon relapse. The abnormally elevated osteoclast count and resorption surfaces are reduced, and at the low dose there is no accumulation of osteoid. The medication is generally well tolerated and at the recommended dosage there is no evidence of increased fracture rate.

UI	MeSH Term	Description	Entries
D010001	Osteitis Deformans	A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry.	Paget's Disease of Bone,Osseous Paget's Disease,Paget Disease of Bone,Paget Disease, Bone,Pagets Disease, Bone
D004305	Dose-Response Relationship, Drug	The relationship between the dose of an administered drug and the response of the organism to the drug.	Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006909	Hydroxyproline	A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.	Oxyproline,4-Hydroxyproline,cis-4-Hydroxyproline,4 Hydroxyproline,cis 4 Hydroxyproline
D000206	Actuarial Analysis	The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.	Analysis, Actuarial,Actuarial Analyses,Analyses, Actuarial
D000469	Alkaline Phosphatase	An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1.
D012968	Etidronic Acid	A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.	EHDP,Ethanehydroxydiphosphonate,Etidronate,Etidronate Disodium,Sodium Etidronate,(1-hydroxyethylene)diphosphonic acid,(1-hydroxyethylene)diphosphonic acid, Tetrapotassium Salt,1,1-hydroxyethylenediphosphonate,1-Hydroxyethane-1,1-Diphosphonate,1-Hydroxyethylidene-1,1-Bisphosphonate,Dicalcium EHDP,Dicalcium Etidronate,Didronel,Disodium 1-Hydroxyethylene Diphosphonate,Disodium Etidronate,Ethanehydroxyphosphate,Etidronate, Tetrapotassium Salt,HEDP,HEDSPA,Hydroxyethanediphosphonate,Hydroxyethylidene Diphosphonic Acid,Phosphonic acid, (1-hydroxyethylidene)bis-, disodium salt,Xidifon,Xidiphon,Xydiphone,1 Hydroxyethane 1,1 Diphosphonate,1 Hydroxyethylidene 1,1 Bisphosphonate,1,1 hydroxyethylenediphosphonate,1-Hydroxyethylene Diphosphonate, Disodium,Diphosphonate, Disodium 1-Hydroxyethylene,Diphosphonic Acid, Hydroxyethylidene,Disodium 1 Hydroxyethylene Diphosphonate,EHDP, Dicalcium,Etidronate, Dicalcium,Etidronate, Disodium,Etidronate, Sodium,Salt Etidronate, Tetrapotassium,Tetrapotassium Salt Etidronate
D050723	Fractures, Bone	Breaks in bones.	Bone Fractures,Broken Bones,Spiral Fractures,Torsion Fractures,Bone Fracture,Bone, Broken,Bones, Broken,Broken Bone,Fracture, Bone,Fracture, Spiral,Fracture, Torsion,Fractures, Spiral,Fractures, Torsion,Spiral Fracture,Torsion Fracture